SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2018
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms SAFE-HEaRt
- 19 Dec 2018 Planned End Date changed from 1 Aug 2018 to 1 Mar 2019.
- 19 Dec 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Jan 2019.
- 19 Dec 2018 Status changed from recruiting to active, no longer recruiting.